Q-omics provides the consensus-scored RPL24P9 profile across patient tissues and cancer cell-line models. RPL24P9 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RPL24P9 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, RPL24P9 RNA expression shows 6,228 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, KIRC, and STAD as cancer lineages where RPL24P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL24P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL24P9 survival associations across molecular data types. RPL24P9 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL24P9 RNA expression–survival associations across cancer types. High RPL24P9 expression shows unfavorable associations in BRCA, PAAD, ESCA and LUSC, but favorable associations in HNSC and UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .033). Together, the overview and detailed table identify BRCA as the clearest survival context for RPL24P9 RNA expression.
This table summarizes RPL24P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL24P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL24P9 shows lower tumor expression in HNSC and higher tumor expression in KIRC, HNSC and COAD. The KIRC box plot shows higher RPL24P9 RNA expression in tumor versus normal tissue (log2 FC = +0.454, t-test p < 0.001).
This table shows molecular features associated with RPL24P9 in patient tissues and cancer cell lines. In patient samples, RPL24P9 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
